In another phase III study evaluating onartuzumab, 636 NSCLC patients with varying EGFR and MET mutational statuses were included and treated with either erlotinib and onartuzumab or erlotinib and placebo. This evidence concerns the gene EGFR and non-small cell lung carcinoma.